<DOC>
	<DOCNO>NCT00738023</DOCNO>
	<brief_summary>Insulin resistance implicate central pathogenetic feature cardiovascular risk factor cluster include hypertension , impair glucose tolerance , diabetes , dyslipidemia , hemostatic disorder . Recent evidence suggest increase level free fatty acid ( FFA ) obese subject lead candidate pathogenesis insulin resistance ( 1-4 ) . In preliminary study effect FFA insulin secretion action ( lipotoxicity ) , observed infusion Intralipid/heparin increase FFA ~ four-fold-baseline level 48 hour result significant reproducible raise systolic diastolic blood pressure ( BP ) obese African American subject without diabetes . The increase blood pressure apparent 12 hour infusion , reach peak increment 32 mm Hg systolic 14 mm Hg diastolic pressure 24 hour . These preliminary finding indicate , addition well-known effect insulin resistance , sustain elevation FFA result development acute metabolic syndrome .</brief_summary>
	<brief_title>Free Fatty Acid-Induced Hypertension Obese Subjects With Type 2 Diabetes</brief_title>
	<detailed_description>The FFA-induced hypertension constitutes useful model examine disease mechanism test new therapeutic intervention correct different disorder associate insulin resistance metabolic syndrome . The effect FFA insulin action well establish ( 4-6 ) ; however , pressor effect FFA infusion obese subject investigate . We hypothesize observed change blood pressure result acute endothelial dysfunction due increase FFA concentration ; rosiglitazone , PPAR gamma receptor agonist , protect FFA-induced elevation blood pressure endothelial dysfunction obese subject .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<criteria>Males female age 18 70 year . Subjects must BMI ≥ 30 kg/m2 . Subjects must BP &lt; 130/80 mm Hg prior history hypertension . A known history type 2 diabetes mellitus &lt; 3 year ( 5 year ) . Subjects must HbA1c &lt; 9 % . Diabetic subject must receive current antidiabetic therapy stable dos sulfonylureas last 2 month . Subjects must able understand willing adhere study protocol . Subjects history hypertension ( BP &gt; 140/90 mm HG ) receive antihypertensive drug therapy prior study . Obese nondiabetic control impair glucose tolerance ( 2hour glucose 140 199 mg/dl ) 75g OGTT . Diabetic subject require insulin therapy receive insulin sensitizer agent ( metformin , rosiglitazone , pioglitazone ) within 3 month enter study ( SV1 , week2 ) . Subjects fast triglyceride level &gt; 250 mg/dL prior study ( SV1 , week2 ) . Clinically relevant hepatic disease ( ALT 2.5x &gt; upper limit normal ) , significant medical surgical illness . Renal failure , show serum creatinine ≥1.5 mg/dL male , ≥ 1.4 mg/dL female . Mental condition render subject unable understand nature , scope , possible consequence study . Female subject pregnant breast feeding time enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>diabetes ,</keyword>
	<keyword>hypertension ,</keyword>
	<keyword>free-fatty acid</keyword>
</DOC>